SEARCH

SEARCH BY CITATION

References

  • 1
    Dougherty TJ, Kaufman JE, Goldfarb A, et al. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978;38:262835.
  • 2
    Gaulloer JM, Berg K, Peng Q, et al. Use of 5-ALA to improve PDT on cells in culture. Cancer Res 1997;57:14816.
  • 3
    Fink-Puches R, Hofer A, Smolle J, et al. Primary clinical responses and long-term follow-up of SKs treated with topically applied 5-ALA and irradiation by different wavelengths of light. J Photochem Photobiol B Biol 1997;41:14551.
  • 4
    Kennedy JC, Pottier RH, Pross DC Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B Biol 1990;6:1438.
  • 5
    Lehmann P. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol 2007;156:793801.
  • 6
    Morton CA. Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol Clin 2007;25:817.
  • 7
    Szeimies RM. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin 2007;25:8994.
  • 8
    Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 1: Photochemistry and photobiology. J Eur Acad Dermatol Venereol 2007;21:293302.
  • 9
    Brancaleon L. Lasers and non-laser light sources for PDT. Lasers Med Sci 2002;17:17386.
  • 10
    Peng Q, Warloe T, Berg K, et al. 5-ALA based PDT. Clinical research and future challenges. Cancer 1997;79:2282308.
  • 11
    Peng Q, Berg K, Moan J, et al. 5-ALA based PDT; principles and experimental research. Photochem Photobiol 1997;65:23551.
  • 12
    Braathen L, Szeimies R, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007;56:12543.
  • 13
    Alster TS, Tanzi EL, Welsh EC. Photorejuvenation of facial skin with topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a split-face comparison study. J Drugs Dermatol 2005;4:358.
  • 14
    Dover JS, Bhatia AC, Stewart B, Arndt KA. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol 2005;141:124752.
  • 15
    Zakhary K, Ellis D. Applications of aminolevulinic acid-based PDT in cosmetic facial practices. Facial Plast Surg 2005;21:1106.
  • 16
    Gold MH, Bradshaw VL, Boring MM, et al. Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. Dermatol Surg 2006;32:795801.
  • 17
    Nootheti PK, Goldman MP. Aminolevulinic acid-photodynamic therapy for photorejuvenation. Dermatol Clin 2007;25:3545.
  • 18
    Ruiz-Rodriguez R, Lopez-Rodriguez L. Nonablative skin resurfacing: the role of PDT. J Drugs Dermatol 2006;5:75662.
  • 19
    Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for AKs. J Am Acad Dermatol 1995;32:958.
  • 20
    Kalisiak MS, Rao J. Photodynamic therapy for actinic keratoses. Dermatol Clin 2007;25:1523.
  • 21
    Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 2001;45:96104.
  • 22
    Jeffes EW. Levulan: the first approved topical photosensitizer for the treatment of actinic keratosis. J Dermatol Treat 2002;13 (Suppl 1):S1923.
  • 23
    Nakaseko H, Kobayashi M, Akita Y, et al. Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses. Br J Dermatol 2003;148:1227.
  • 24
    Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004;140:416.
  • 25
    Touma D, Yaar M, Whitehead S, et al. trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004;140:3340.
  • 26
    Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol 2003;139:131320.
  • 27
    Gold MH. The evolving role of aminolevulinic acid hydrochloride with photodynamic therapy in photoaging. Cutis 2002;69 (6 Suppl):813.
  • 28
    Fritsch C, Stege H, Saalmann G, et al. Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses. Photodermatol Photoimmunol Photomed 1997;13:1815.
  • 29
    Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999;41:4148.
  • 30
    Kasche A, Luderschmidt S, Ring J, Hein R. Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol 2006;5:3536.
  • 31
    Szeimies RM, Karrer, S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:25862.
  • 32
    Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 2: clinical results. J Eur Acad Dermatol Venereol 2007;21:43951.
  • 33
    Fritsch C, Homey B, Stahl W, et al. Preferential relative porphyrin enrichment in solar keratoses upon topical application of ALA methylester. Photochem Photobiol 1998;68:21821.
  • 34
    Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48:22732.
  • 35
    Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol 1982;7:6312.
  • 36
    Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999;41:4148.
  • 37
    Kim HS, Yoo JY, Cho KH, et al. Topical photodynamic therapy using intense pulsed light for treatment of actinic keratosis: clinical and histopathologic evaluation. Dermatol Surg 2005;31:336.
  • 38
    Tschen EH, Wong DS, Phase IV ALA-PDT Actinic Keratosis Study Group. et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol 2006;155:12629.
  • 39
    Redbord KP, Hanke CW. Topical photodynamic therapy for dermatologic disorders: results and complications. J Drugs Dermatol 2007;6:1197202.
  • 40
    Zane C, Capezzera R, Sala R, et al. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med 2007;39:2039.
  • 41
    Lang K, Bolsen K, Stahl W, et al. The 5-aminolevulinic acid-induced porphyrin biosynthesis in benign and malignant cells of the skin. J Photochem Photobiol B 2001;65:2934.
  • 42
    Kelty C, Brown N, Reed W, Ackroyd D. The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci 2002;1:15868.
  • 43
    Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000;142:3389.
  • 44
    Gold MH, Bradshaw VL, Boring MM, et al. Treatment of sebaceous gland hyperplasia by photodynamic therapy with 5-aminolevulinic acid and a blue light source or intense pulsed light source. J Drugs Dermatol 2004;3 (6 Suppl):S69.
  • 45
    Goldman MP, Atkin D, Kincad S. PDT/ALA in the treatment of actinic damage: real world experience. J Lasers Surg Med 2002;14 (S):24.
  • 46
    Avram DK, Goldman MP. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol 2004;3 (1 Suppl):S369.
  • 47
    Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 1994;130:74351.
  • 48
    Fijan S, Hönigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 1995;133:2828.
  • 49
    Fink-Puches R, Soyer HP, Hofer A, et al. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998;134:8216.
  • 50
    Baptista J, Martinez C, Leite L, Cochito M. Our PDT experience in the treatment of non-melanoma skin cancer over the last 7 years. J Eur Acad Dermatol Venereol 2006;20:6937.
  • 51
    Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol 1995;29:537.
  • 52
    Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001;144:83240.
  • 53
    Basset-Seguin N, Ibbotson S, Emterstam L, et al. MAL-PDT vs cryotherapy in primary sBCC: results of 36 month follow up. J Eur Acad Dermatol Venerol 2004;18 (suppl 2):412.
  • 54
    Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med 2008;40:1538.
  • 55
    Nikkels AF, Piérard-Franchimont C, Nikkels-Tassoudji N, et al. Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas. Acta Clin Belg 2005;60:22734.
  • 56
    Wu JK, Siller G, Whitehead K. Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australas J Dermatol 2003;44:1235.
  • 57
    Rhodes LE, De Rie M, Enström Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004;140:1723.
  • 58
    Bapstista J, Martinez C, Leite L, Cochito M. Our PDT experience in the treatment of non-melanoma skin cancer over the last 7 years. J Eur Acad Dermatol Venerol 2006;20:6937.
  • 59
    Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000;42:389413.
  • 60
    Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000;142:3389.
  • 61
    Soler AM, Warloe T, Tausjø J, Berner A. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Derm Venereol 1999;79:2046.
  • 62
    Thissen MR, De Blois MW, Robinson DJ, et al. PpIX fluorescence kinetics and increased skin damage after intracutaneous injection of 5-aminolevulinic acid and repeated illumination. J Invest Dermatol 2002;118:23945.
  • 63
    Morton CA, Whitehurst C, McColl JH, et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001;137:31924.
  • 64
    Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol 2000;143:12705.
  • 65
    Soler AM, Angell-Petersen E, Warloe T, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. J Photochem Photobiol 2000;71:7249.
  • 66
    De Haas ER, Kruijt B, Sterenborg HJ, et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 2006;126:267986.
  • 67
    De Blois AW, Grouls RJ, Ackerman EW, Wijdeven WJ. Development of a stable solution of 5-aminolaevulinic acid for intracutaneous injection in photodynamic therapy. Lasers Med Sci 2002;17:20815.
  • 68
    Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001;145:46771.
  • 69
    Tope WD, Menter A, El-Azhary RA, et al. Comparison of topical MAL PDT vs placebo PDT in noduar BCC. J Eur Acad Dermatol Venerol 2004;18 (Suppl 2):4134.
  • 70
    Vinciullo, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for ‘difficult-to-treat’ basal cell carcinoma. Br J Dermatol 2005;152:76572.
  • 71
    Horn M, Wolf P, Wulc HC, et al. Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional therapy. Br J Dermatol 2003;149:12429.
  • 72
    Kuijpers DI. BCC: treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol 2002;3:24759.
  • 73
    Harth Y, Hirshovitz B. Topical photodynamic therapy in basal and squamous cell carcinoma and penile Bowen's disease with 20% aminolevulinic acid, and exposure to red light and infrared light. Harefuah 1998;134:6025.
  • 74
    Wennberg AM, Lindholm LE, Alpsten M, Larkö O. Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Arch Dermatol Res 1996;288:5614.
  • 75
    Foley P, Freeman M, Siller G, et al. MAL-PDT or placebo cream in nodular basal cell carcinoma: results of an Australian double-blind randomized multicenter study. Poster presented at the International Skin Cancer Conference. 2004 Zurich, July 22–24, 2004.
  • 76
    Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007;6:50713.
  • 77
    Stables GI, Stringer MR, Robinson DJ, Ash DV. Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy. Br J Dermatol 1997;136:95760.
  • 78
    Morton CA, Whitehurst C, McColl JH, et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001;137:31924.
  • 79
    Morton CA, Whitehurst C, Moore JV, MacKie RM. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000;143:76772.
  • 80
    Britton JE, Goulden V, Stables G, et al. Investigation of the use of the pulsed dye laser in the treatment of Bowen's disease using 5-aminolaevulinic acid phototherapy. Br J Dermatol 2005;153:7804.
  • 81
    Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003;148:53943.
  • 82
    Morton C, Horn M, Lehman J, et al. A 24-month update of a placebo controlled European study comparing MAL-PDT with cryotherapy and 5-fluorouracil in patient's with Bowen's disease. J Eur Acad Dermatol Venerol 2005;19 (Suppl 2):2378.
  • 83
    Morton CA, Whitehurst C, Moseley H, et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996;135:76671.
  • 84
    Varma S, Wilson H, Kurwa HA, et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001;144:56774.
  • 85
    Thestrup-Pedersen K, Ravnborg L, Reymann F. Morbus Bowen. A description of the disease in 617 patients. Acta Derm Venereol 1988;68:2369.
  • 86
    Goldman MP, Atkin D, Kincad S. PDT/ALA in the treatment of actinic damage: real world experience. J Lasers Surg Med 2002;14 (S):24.
  • 87
    Avram DK, Goldman MP. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol 2004;3 (1 Suppl):S369.
  • 88
    Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic Photorejuvenatioin. Dermatol Surg 2002;28:7424.
  • 89
    Key DJ. Aminolevulinic acid-pulsed dye laser photodynamic therapy for the treatment of photoaging. Cosmetic Dermatol 2005;18:3116.
  • 90
    Marmur ES, Phelps R, Goldberg DJ. Ultrastructural changes seen after ALA-IPL photorejuvenation: a pilot study. J Cosmet Laser Ther 2005;7:214.
  • 91
    Ho WL, Murphy GM. Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients. Br J Dermatol 2008;158:21724.
  • 92
    Herman S, Rogers HD, Ratner D. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients. Skinmed 2007;6:2348.
  • 93
    Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. JEADV 2006;86:258.
  • 94
    Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004;151:196200.
  • 95
    Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004;77:11521.
  • 96
    Perrett CM, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007;156:3208.
  • 97
    Tierney E, Eide M, Jacobsen G, Ozog D. Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes. J Cosmet Laser Ther 2008;10:816.
  • 98
    Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol 2008;7:235.